Camidge DR et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of Phase III ALTA-1L trial. J Thorac Oncol 2021;16(12):2091-108. Abstract
Carrizosa DR et al. CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions. ASCO 2022;Abstract 3006.
Drilon A et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov 2022;[Online ahead of print]. Abstract
Drilon A et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 Phase I/II trial. J Clin Oncol 2023;41(2):385-94. Abstract
Goto K et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant metastatic non-small cell lung cancer: Interim results from the phase 2 DESTINY-Lung02 trial. ESMO 2022;Abstract LBA55.
Griesinger F et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial. Ann Oncol 2022;33(11):1168-78. Abstract
Hotta K et al. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. ESMO Open 2022;7(4):100527. Abstract
Jänne PA et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 2022;387(2):120-31. Abstract
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract
Jänne PA et al. Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ESMO 2022;Abstract LBA4.
Johnson ML et al. Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRASG12C mutation: CodeBreaK 200 phase III study. ESMO 2022;Abstract LBA10.
Krebs M et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. ASCO 2022;Abstract 9008.
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Minchom A et al. Patient-reported outcomes with selpercatinib among patients with RET fusion-positive non-small cell lung cancer in the Phase I/II LIBRETTO-001 trial. Oncologist 2022;27(1):22-9. Abstract
Park K et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol 2021;39(30):3391-402. Abstract
Piotrowska Z et al. ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib. ESMO 2022;Abstract LBA53.
Ramalingam SS et al. Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP). ESMO 2022;Abstract 988P.
Shu CA et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. ASCO 2022;Abstract 9006.
Smit EF et al. Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial. ESMO 2022;Abstract 975P.
Solomon BJ et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 2022;[Online ahead of print]. Abstract
Solomon BJ et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol 2022;40(31):3593-602. Abstract
Tsuboi M et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. ESMO 2022;Abstract LBA47.
Wu Y-L et al. Postoperative chemotherapy use and outcomes from ADAURA: Osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 2022;17(3):423-33. Abstract
Yu HA et al. Phase (ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (ins20). ASCO 2022;Abstract 9007.